Clinical Trials on Prostate Carcinoma Metastatic to the Bone

Total 742 results

Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Prostate Carcinoma Metastatic to the Bone

United States
Carolina Research Professionals, LLC
Astellas Pharma Inc

Completed

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

Prostate Carcinoma Metastatic to the Bone

United States
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Castration Resistant Prostate Cancer | Prostate Carcinoma Metastatic to the Bone

United States
University of Utah

Completed

Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the Bone

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Bayer; Janssen, LP; Prostate Cancer Clinical Trials Consortium

Completed

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

Stage IV Prostate Adenocarcinoma | Hormone-refractory Prostate Cancer | Prostate Carcinoma Metastatic to the Bone

United States
Roswell Park Cancer Institute

Withdrawn

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Carcinoma in the Soft Tissue | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | PSA...

United States
Northwestern University
National Cancer Institute (NCI); Vasgene Therapeutics, Inc

Active, not recruiting

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Progressive Disease | Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Adenocarcinoma | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | Castration-Resistant Prostate Carcinoma Refractory to Second-Generation... and other conditions

United States
Stanford University
National Cancer Institute (NCI)

Terminated

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Hormone-Resistant Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Unknown

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
Dana Mathews

Withdrawn

68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer

Prostate Cancer | Prostate Cancer Metastatic | Prostate Cancer Metastatic to Bone

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IV Prostate Cancer AJCC v7

United States
University of California, San Francisco
National Cancer Institute (NCI)

Terminated

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

PSA Progression | Metastatic Prostate Carcinoma in the Soft Tissue | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma in the Soft Tissue | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States, Puerto Rico
University of Washington
National Cancer Institute (NCI)

Completed

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
University of Wisconsin, Madison
Prostate Cancer Foundation; Madison Vaccines, Inc

Completed

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Roswell Park Cancer Institute
AbbVie

Completed

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Carcinoma in the Soft Tissue | Castration Levels of Testosterone | Prostate Carcinoma...

United States
OHSU Knight Cancer Institute
Astellas Pharma US, Inc.; Oregon Health and Science University

Active, not recruiting

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7

United States
Imperial College London
Wellcome Trust; Imperial Clinical Trials Unit (ICTU)

Completed

PROState Pathway Embedded Comparative Trial (IP3-PROSPECT)

Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate Cancer

United Kingdom
Sidney Kimmel Cancer Center at Thomas Jefferson...
Novartis; Prostate Cancer Clinical Trials Consortium

Completed

Enzalutamide With Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer | Prostate Carcinoma Metastatic in the Bone

United States
Sir Mortimer B. Davis - Jewish General Hospital

Terminated

Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer (CROSSBOW)

Prostatic Neoplasms | Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Metastatic Prostatic Adenocarcinoma | Metastatic Prostate Carcinoma in the Soft Tissue

Canada
Roswell Park Cancer Institute
Dendreon

Completed

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

Metastatic Malignant Neoplasm in the Bone | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

Metastatic Malignant Neoplasm in the Bone | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the Bone

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
M.D. Anderson Cancer Center

Active, not recruiting

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma | Castration-Resistant...

United States
QSAM Therapeutics, Inc.

Recruiting

A Dose Finding Study to Treat Bone Tumor(s)

Bone Cancer | Solid Tumor | Bone Tumor | Metastatic Cancer to the Bone | Metastatic Tumor to the Bone

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Carcinoma Metastatic in the Bone

United States
Massachusetts General Hospital
Bayer

Completed

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to Bone

United States
Jonsson Comprehensive Cancer Center

Terminated

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
University of California, San Francisco
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Not yet recruiting

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Castration-Resistant Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IVB Prostate Cancer AJCC v8

United States
Amsterdam UMC, location VUmc

Active, not recruiting

Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy (RaRe)

Prostate Cancer Metastatic to Bone

Netherlands
Herlev Hospital

Unknown

Diagnostic Imaging of Bone Metastases in Prostate Cancer Patients (DIMAB)

Prostate Cancer Metastatic to Bone

Denmark
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate... and other conditions

United States
University of Washington
Bayer

Recruiting

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
Stony Brook University
The University of Texas Health Science Center at San Antonio

Recruiting

Definitive Radiation for High-Risk Spine Metastases

Metastatic Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastasis | Spine Metastases | Metastatic Tumor | Metastatic Tumor of Bone | Metastatic Tumor to the Spine

United States
Andrew J. Armstrong, MD
Novartis Pharmaceuticals

Terminated

BKM120 in Metastatic Castration-resistant Prostate Cancer

Prostate Cancer | Metastatic (Spread to Other Areas of the Body)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

Lymphadenopathy | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | Prostate Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Suspended

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Lymph Nodes

United States
Spanish Breast Cancer Research Group
Novartis Pharmaceuticals

Completed

Study of the Utility of the BOMET-QOL Questionnaire Patients With Breast Cancer and Bone Metastasis (MAbomet)

Breast Carcinoma Metastatic to the Bone

Spain
National Cancer Institute (NCI)

Terminated

Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
University of Utah

Active, not recruiting

Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer (SOAR)

Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Recurrent Prostate Carcinoma | Oligometastasis | PSA Failure

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Dual Energy Computed Tomography (CT) in Finding Bone Metastases in Patients With Cancer

Malignant Neoplasm | Metastatic Malignant Neoplasm to the Bone

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma | Castration-Sensitive Prostate Carcinoma

United States
University of Utah
Bayer

Completed

Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone (RROPE)

Prostate Cancer Metastatic to Bone

United States
University Health Network, Toronto

Completed

Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC (SubDueP)

Metastatic Prostate Cancer | Bone Metastasis

Canada
University of Washington

Active, not recruiting

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Castration-Resistant Prostate Carcinoma | Homologous Recombination Deficiency | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone | ATM Gene Mutation | Prostate Carcinoma Metastatic in the Bone | PSA Level Greater...

United States
Memorial Sloan Kettering Cancer Center

Withdrawn

Detection of Acid Sphingomyelinase/Ceramide Pathway Activation in Radiotherapy Patients Using Intravoxel Incoherent Motion (IVIM) Diffusion-weighted Magnetic Resonance Imaging and Serum Biomarkers

Metastatic Disease to Bone | Metastatic Disease to Soft Tissue

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
Rigshospitalet, Denmark

Recruiting

Fully Constrained Acetabular Liner vs. Dual Mobility Hip Joint in the Surgical Treatment of Metastatic Bone Disease of the Hip

Metastatic Cancer to the Hip

Denmark
Rush University Medical Center

Completed

Blood Volume Assessment of Hepatocellular and Metastatic Carcinomas in the Liver

Hepatocellular Carcinoma | Metastatic Carcinoma to the Liver

United States

Clinical Trials on Prostate Carcinoma Metastatic to the Bone

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations